> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Immunic Expects $132 Million To Fund Operations Into Late 2027 Ahead Of MS Results
- URL: https://www.bullished.co/immunic-expects-132-million-to-fund-operations-into-late-2027-ahead-of-ms-results-140a51b8/
- Published: 2026-11-13T13:06:14.000Z
- Updated: 2026-11-13T13:06:14.000Z
- Description: December trial results will determine whether the company pursues its planned U.S. drug-approval application in mid-2027.
- Author: Matteo Parrino
- Tags: SEC Filings, IMUX, Industry: Healthcare

[Immunic](https://www.bullished.co/tag/imux/), which is testing an oral multiple-sclerosis drug, reported [$132 million in cash](https://www.prnewswire.com/news-releases/immunic-inc-reports-third-quarter-2026-financial-results-and-provides-corporate-update-302938612.html?ref=bullished.co) and equivalents Friday and expects it to finance operations into late 2027\. The earnings release accompanying its [SEC filing](https://www.sec.gov/Archives/edgar/data/0001280776/000149315226051543/form8-k.htm?ref=bullished.co) puts that funding estimate under its current operating plan, with pivotal trial results expected in December.

## December Sets The Approval Path

Immunic expects December results from its fully enrolled late-stage relapsing-MS trials of vidofludimus calcium. Positive findings would support a planned [U.S. approval application](https://www.sec.gov/Archives/edgar/data/0001280776/000149315226051543/ex99-1.htm?ref=bullished.co) in mid-2027; the company targets potential approval in 2028.

The twin studies, ENSURE-1 and ENSURE-2, randomized [1,121 and 1,100 patients](https://www.prnewswire.com/news-releases/immunic-inc-reports-third-quarter-2026-financial-results-and-provides-corporate-update-302938612.html?ref=bullished.co), respectively, across more than 100 sites in 15 countries. The drug remains investigational, and its safety and effectiveness have not been established.

Chief Executive Officer Erik Lundgren said Immunic is becoming a "[fully integrated commercial](https://www.sec.gov/Archives/edgar/data/0001280776/000149315226051543/ex99-1.htm?ref=bullished.co) organization." The company has no approved products and has generated no revenue from product sales.

Immunic added Jaa Roberson as chief people officer, effective October 19, and Chitrang Davé as chief data and digital officer, effective September 1\. Their roles cover talent management and data, analytics, AI and digital strategy as the company prepares for a possible application and commercialization.

## Approval Preparations Add To Spending

Third-quarter research spending rose to $23.9 million from $20.0 million a year earlier. Immunic attributed the increase to staffing, drug supplies and approval preparations, partly offset by lower trial expenses.

Approval-readiness costs increased $2.9 million, drug-supply costs rose $1.4 million and personnel expenses increased $1.9 million. Expenses for the relapsing-MS and progressive-MS trials fell $1.8 million and $1.0 million, respectively.

Administrative expenses reached $19.4 million, versus $6.0 million a year earlier. The company attributed most of the increase to personnel costs, including $9.7 million in additional non-cash stock compensation primarily associated with a separation agreement. Legal and consultancy costs increased $1.3 million, and pre-commercial marketing costs rose $0.6 million.

Total operating expenses were $43.4 million, including $13.9 million in non-cash charges, mainly stock compensation. Net loss widened to approximately $42.3 million from $25.6 million, but loss per share narrowed to $0.99 from $1.32\. The weighted-average share count rose to 42,797,370 from 19,389,776.

For the first nine months, research and administrative expenses were $75.5 million and $36.4 million, versus $62.9 million and $17.0 million. Net loss reached approximately $109 million, versus $77.9 million. Quarterly interest income increased to $1.1 million from $0.4 million, which Immunic attributed to higher average cash balances following its February 2026 private placement.

## A Second MS Program Takes Shape

Immunic is preparing another late-stage vidofludimus calcium trial, PROTECT-MS, for progressive multiple sclerosis. It expects the first patient to enroll in the first half of 2027\. The company [hosted a research event](https://www.sec.gov/Archives/edgar/data/0001280776/000119380526001432/e665870%5F8k-immunic.htm?ref=bullished.co) focused on progressive MS on Thursday, November 5.

The program draws on its mid-stage CALLIPER study. At MSToronto2026 in October, Immunic presented follow-up findings in which favorable disability trends appeared to persist among patients continuing treatment. The company cautioned that the extension lacked a placebo group and included patients who chose to continue.

Immunic's earlier programs include IMU-381, still in preclinical testing with lead-candidate selection underway, and IMU-856, designed to restore the intestinal barrier.

December's relapsing-MS results are the next clinical milestone—and positive results are the condition for Immunic's planned mid-2027 approval application.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — IMMUNIC, INC. (IMUX)](https://www.sec.gov/Archives/edgar/data/0001280776/000149315226051543/form8-k.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit ex99-1.htm — IMMUNIC, INC. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001280776/000149315226051543/ex99-1.htm?ref=bullished.co) — SEC EDGAR
- [Immunic, Inc. Reports Third Quarter 2026 Financial Results and Provides Corporate Update](https://www.prnewswire.com/news-releases/immunic-inc-reports-third-quarter-2026-financial-results-and-provides-corporate-update-302938612.html?ref=bullished.co) — prnewswire.com
- [8-K filed 2026-11-05 — IMMUNIC, INC. (earlier disclosure)](https://www.sec.gov/Archives/edgar/data/0001280776/000119380526001432/e665870%5F8k-immunic.htm?ref=bullished.co) — SEC EDGAR

### More on Immunic

- [Immunic Puts Progressive Multiple Sclerosis Research On Its Webinar Agenda](https://www.bullished.co/immunic-puts-progressive-multiple-sclerosis-research-on-its-webinar-agenda-583871d9/)

[All Immunic (IMUX) coverage →](https://www.bullished.co/tag/imux/)